Page last updated: 2024-08-25

oxazolidin-2-one and Dementia Praecox

oxazolidin-2-one has been researched along with Dementia Praecox in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Candler, J; Doran, AC; Duplantier, AJ; Efremov, I; Ganong, AH; Haas, JA; Hanks, AN; Kraus, KG; Lazzaro, JT; Lu, J; Maklad, N; McCarthy, SA; O'Sullivan, TJ; Rogers, BN; Siuciak, JA; Spracklin, DK; Zhang, L	1
Brnardic, EJ; Culberson, C; Fillgrove, KL; Fraley, ME; Garbaccio, RM; Hartman, GD; Huszar, SL; Hutson, PH; Jacobson, MA; Kuo, Y; Layton, ME; Magliaro, BC; O'Brien, JA; Sanders, JM; Sur, SM; Tang, C; Uslaner, JM	1
Gross-Isseroff, R; Hermesh, H; Magen, A; Shiloh, R; Weizman, A	1

Trials

1 trial(s) available for oxazolidin-2-one and Dementia Praecox

Article	Year
The 5-HT1D receptor agonist zolmitriptan for neuroleptic-induced akathisia: an open label preliminary study. International clinical psychopharmacology, 2005, Volume: 20, Issue:1 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Oxazolidinones; Psychiatric Status Rating Scales; Schizophrenia; Serotonin; Serotonin Receptor Agonists; Treatment Outcome; Tryptamines	2005

Article

Year

The 5-HT1D receptor agonist zolmitriptan for neuroleptic-induced akathisia: an open label preliminary study.

International clinical psychopharmacology, 2005, Volume: 20, Issue:1

Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Oxazolidinones; Psychiatric Status Rating Scales; Schizophrenia; Serotonin; Serotonin Receptor Agonists; Treatment Outcome; Tryptamines

2005

Other Studies

2 other study(ies) available for oxazolidin-2-one and Dementia Praecox

Article	Year
3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization. Bioorganic & medicinal chemistry letters, 2009, May-01, Volume: 19, Issue:9 Topics: Administration, Oral; Allosteric Regulation; Allosteric Site; Carbamates; Chemistry, Pharmaceutical; Drug Design; Humans; Inhibitory Concentration 50; Ligands; Microsomes; Models, Chemical; Molecular Structure; Oxazolidinones; Receptors, Metabotropic Glutamate; Schizophrenia	2009
3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts. Bioorganic & medicinal chemistry letters, 2010, May-15, Volume: 20, Issue:10 Topics: Allosteric Regulation; Animals; Antipsychotic Agents; Ketamine; Oxazolidinones; Rats; Receptors, Metabotropic Glutamate; Schizophrenia; Structure-Activity Relationship	2010

Article

Year

3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization.

Bioorganic & medicinal chemistry letters, 2009, May-01, Volume: 19, Issue:9

Topics: Administration, Oral; Allosteric Regulation; Allosteric Site; Carbamates; Chemistry, Pharmaceutical; Drug Design; Humans; Inhibitory Concentration 50; Ligands; Microsomes; Models, Chemical; Molecular Structure; Oxazolidinones; Receptors, Metabotropic Glutamate; Schizophrenia

2009

3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts.

Bioorganic & medicinal chemistry letters, 2010, May-15, Volume: 20, Issue:10

Topics: Allosteric Regulation; Animals; Antipsychotic Agents; Ketamine; Oxazolidinones; Rats; Receptors, Metabotropic Glutamate; Schizophrenia; Structure-Activity Relationship

2010